loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Alkem Laboratories Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Alkem Laboratories Ltd. 13 Nov 2025 14:31 PM
Result PDF

Q2FY26 Quarterly Result Announced for Alkem Laboratories Ltd.

Pharmaceuticals company Alkem Laboratories announced Q2FY26 results

  • Total Revenue from Operations was Rs 40,010 million, with YoY growth of 17.2%.
    • India sales were Rs 27,660 million, YoY growth of 12.4%.
    • International sales were Rs 11,890 million, with YoY growth of 29.5%.
  • Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs 9,208 million, resulting in an EBITDA margin of 23.0% vs 22.0% in Q2FY25. EBITDA grew by 22.3% YoY.
  • R&D expenses for Q2FY26 were Rs 1,302 million, or 3.3% of total revenue from operations, vs Rs 1,465 million in Q2FY25 at 4.3% of total revenue from operations.
  • Profit before tax was Rs 8,958 million, YoY growth of 14.8%.
  • Net Profit (after Minority Interest) was Rs 7,651 million, YoY growth of 11.1%.
  • According to IQVIA (SSA) data, for Q2FY26:
    • In the Acute segment, Alkem became the number one company in IPM this quarter.
    • The Company registered a growth of 6.4% YoY in-line with the Indian Pharmaceutical Market (IPM), which also grew by 6.4%.

Vikas Gupta, CEO, Alkem, said: “Q2FY26 has been another strong quarter for us, marked by robust growth across India, the US, and key international markets. We also saw healthy traction in new product launches across markets. The GST revision is a positive step, and we adapted swiftly to ensure a seamless transition. Our improved gross margins and operating leverage have contributed to a stronger EBITDA profile. As we look ahead, we remain focused on accelerating growth and continue to strengthen our presence in key markets.”

Result PDF

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q1FY26 results

  • Total Revenue from Operations was Rs 33,711 million, with YoY growth of 11.2%.
  • EBITDA were Rs 7,391 million, resulting in an EBITDA margin of 21.9% vs 20.1% in Q1FY25, EBITDA grew by 21.4% YoY.
  • Profit before tax before exceptional items was Rs 7,581 million, YoY growth of 22.4%.
  • Net Profit (after Minority Interest) was Rs 6,643 million, YoY growth of 21.8%.
  • R&D expenses for Q1FY26 were Rs 1,184 million, or 3.5% of total revenue from operations, vs Rs 1,257 million in Q1FY25 at 4.1% of total revenue from operations.

Vikas Gupta, CEO, Alkem, said: “Q1FY26 marked a strong start to the year, with healthy growth across both our domestic and international markets. Our performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile. These results reflect the disciplined execution of our strategy, focused investments, and a deliberate pivot toward value-accretive products and markets with a sharper focus on EBITDA. We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions.”

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Total Revenue from Operations was Rs 31,438 million, with YoY growth of 7.1%.
    • India sales were Rs 21,355 million, YoY growth of 8.1%.
    • International sales were Rs 9,747 million, with YoY growth of 7.2%.
  • Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs 3,913 million, resulting in an EBITDA margin of 12.4% vs. 13.7% in Q4FY24. EBITDA declined by 2.7% YoY.
  • R&D expenses for Q4FY25 were Rs 1,585 million, or 5.0% of total revenue from operations, compared to Rs 1,757 million in Q4FY24 at 6.0% of total revenue from operations.
  • Profit before tax before exceptional items was Rs 3,963 million, YoY growth of 4.3%.
  • Net Profit (after Minority Interest) was Rs 3,059 million, YoY growth of 4.2%.
  • According to IQVIA (SSA) data, for Q4FY25:
    • The Company registered a growth of 6.5% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 6.9%.
    • The acute segment growth outperformed IPM by 150 bps at 7.5%.

FY25 Financial Highlights:

  • Total Revenue from Operations was Rs 129,645 million, with YoY growth of 2.3%.
    • India sales were Rs 89,837 million, with YoY growth of 6.5%.
    • International sales were Rs 38,210 million, with YoY de-growth of 4.5%.
  • Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs 25,122 million, resulting in an EBITDA margin of 19.4% vs. 17.7% in FY24. EBITDA increased by 11.9% YoY.
  • R&D expenses for FY25 were Rs 5,620 million, or 4.3% of total revenue from operations, compared to Rs 5,229 million in FY24 at 4.1% of total revenue from operations.
  • Profit before tax before exceptional items was Rs 25,270 million, YoY growth of 17.8%.
  • Net Profit (after Minority Interest) was Rs 21,655 million, YoY growth of 20.6%.
  • The cash and balance at the end of 31st March, 2025, is Rs46.2 billion.
  • According to IQVIA (SSA) data, for FY25:
    • The Company registered a growth of 6.8% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 7.7%.
    • The acute segment growth has outperformed IPM in FY25 by 30 bps at 6.9%

Commenting on the Q4 & FY25 results, Vikas Gupta, CEO of Alkem, said, “We ended the year on a good note, with healthy growth in our India business during Q4 and improved profitability and margins for the full year. Our domestic business continues to gain momentum, reinforcing our confidence in its long-term growth trajectory. This performance is driven by strong execution and targeted initiatives across our domestic operations. In the international businesses, excluding the Americas, we are seeing good traction, with several key markets making significant contributions to our growth. As we moved forward, we remain focused on strategic growth opportunities and operational excellence to drive sustainable returns.”

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q3FY25 results

  • Total Revenue from Operations was Rs 33,743 million, with YoY growth of 1.5%.
    • India sales were Rs 23,649 million, with YoY growth of 5.9%.
    • International sales were Rs 9,605 million, with YoY de-growth of 6.2%.
  • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 7,594 million, resulting in an EBITDA margin of 22.5% vs. 21.3% in Q3FY24. EBITDA increased by 7.3% YoY.
  • R&D expenses for the quarter were Rs 1,312 million, or 3.9% of total revenue from operations, compared to Rs 1,111 million in Q3FY24 at 3.3% of total revenue from operations.
  • Profit before tax (PBT) before exceptional item was Rs 7,311 million, a growth of 3.5% compared to Rs 7,062 million in Q3FY24.
  • Net Profit (after Minority Interest) was Rs 6,258 million, YoY growth of 5.2%.
  • As per IQVIA (SSA) data, for Q3FY25, the company registered a growth of 6.0% YoY vs. the Indian Pharmaceutical Market (IPM), which grew by 7.2%.

Vikas Gupta, CEO, Alkem, said: “We are pleased to share that the actions we have taken to improve profitability continue to deliver positive results. By concentrating on higher-margin offerings, better aligning with market needs, and implementing cost-saving strategies to reduce inefficiencies, we are seeing growth in our EBITDA margins. Within the domestic market, our focus is on expanding the presence of our flagship brands and strategically enhancing our portfolio. Looking ahead, we are confident that these initiatives will continue to drive sustainable growth and strengthen our market position.”

Result PDF

Pharmaceuticals company Alkem Laboratories announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Total Revenue from Operations was Rs 34,147 million, with YoY de-growth of 0.7%.
    • India sales were Rs 24,610 million, YoY growth of 5.7%.
    • International sales were Rs 9,181 million, with YoY de-growth of 12.9%.
  • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 7,528 million, resulting in an EBITDA margin of 22.0% vs. 21.7% in Q2FY24. EBITDA increased by 0.8% YoY.
  • R&D expenses for the quarter were Rs 1,465 million, or 4.3% of total revenue from operations, compared to Rs 1,158 million in Q2FY24 at 3.4% of total revenue from operations.
  • Profit before tax (PBT) before exceptional item was Rs 7,803 million, a growth of 10.6% compared to Rs 7,057 million in Q2FY24.
  • Net Profit (after Minority Interest) was Rs 6,886 million, YoY growth of 11.0%.
  • As per IQVIA (SSA) data, for Q2FY25, the company registered a growth of 6.3% YoY vs. the Indian Pharmaceutical Market (IPM), which grew by 7.6%.

H1FY25 Financial Highlights:

  • Total Revenue from Operations was Rs 64,465 million, with YoY growth of 0.6%.
    • India sales were Rs 44,833 million, YoY growth of 6.0%.
    • International sales were Rs 18,857 million, with YoY de-growth of 8.8%.
  • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 13,615 million, resulting in an EBITDA margin of 21.1% vs. 17.7% in H1FY24. EBITDA increased by 19.9% YoY.
  • R&D expenses for H1FY25 were Rs 2,722 million, or 4.2% of total revenue from operations, compared to Rs 2,360 million in H1FY24 at 3.7% of total revenue from operations.
  • Profit before tax (PBT) before exceptional item was Rs 13,996 million, a growth of 32.2% compared to Rs 10,586 million in H1FY24.
  • Net Profit (after Minority Interest) was Rs 12,338 million, YoY growth of 36.0%.
  • As per IQVIA (SSA) data, for H1FY25, the company registered a growth of 7.1% YoY vs. the Indian Pharmaceutical Market (IPM), which grew by 8.2%.

Vikas Gupta, CEO of Alkem, said: “We are pleased to share that the outcomes of our strategic initiatives designed to enhance profitability have proven effective. We are prioritising a high-margin product mix, aligning more effectively with market demands, and implementing cost-control measures to mitigate inefficiencies, which are supporting EBITDA margin growth. In the domestic market, our focus remains on augmenting the growth of our large brands and making strategic portfolio additions. We also see significant opportunities for growth in our emerging markets business.”

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q1FY25 results:

  • Total Revenue from Operations was Rs 30,318 million, with YoY growth of 2.2%.
  • India sales were Rs 20,223 million, with YoY growth of 6.4%.
  • International sales were Rs 9,677 million, with YoY de-growth of 4.6%.
  • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 6,086 million, resulting in an EBITDA margin of 20.1% vs. 13.1% in Q1FY24. EBITDA increased by 56.4% YoY.
  • R&D expenses for the quarter were Rs 1,257 million, or 4.1% of total revenue from operations, compared to Rs 1,202 million in Q1FY24 at 4.1% of total revenue from operations.
  • Profit before tax (PBT) before exceptional items was Rs 6,194 million, a growth of 75.5% compared to Rs 3,529 million in Q1FY24.
  • Net Profit (after Minority Interest) was Rs 5,452 million, with YoY growth of 90.1%.
  • According to IQVIA (SSA—Stockist Sales Audit) data, for Q1FY25, the company registered a growth of 8.4% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 8.7%.

Commenting on the Q1FY25 results, Vikas Gupta, CEO of Alkem, said, “We are happy that our efforts to improve profitability have started paying off, and we have seen a marked increase in margins during the quarter. We are committed to maximising our EBITDA margin by carefully managing our product mix, controlling costs, and taking advantage of the favourable raw material pricing environment. The domestic business is our stronghold, and we expect to build on it by furthering the growth of our large brands and bridging portfolio gaps. Simultaneously, we are also focusing on growing our business in emerging markets. During the quarter, an important development was the successful resolution of US FDA’s Form 483 at the Baddi facility. At Alkem, we remain steadfast to prioritising quality and regulatory compliance.”

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Total Revenue from Operations were Rs 29,358 million, YoY growth of 1.1%.
  • India sales were Rs 19,724 million, YoY de-growth of 1.9%.
  • International sales were Rs 9,096 million, YoY growth of 6.1%.
  • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 4,020 million, resulting in EBITDA margin of 13.7% vs. 12.2% in Q4FY23. EBITDA increased by 13.8% YoY.
  • R&D expenses for the quarter was Rs 1,757 million, or 6.0% of total revenue from operations compared to Rs 1,472 million in Q4FY23 at 5.1% of total revenue from operations
  • Profit before tax (PBT) before exceptional item was Rs 3,799 million, a growth of 20.7% compared to Rs 3,146 million in Q4FY23.
  • Net Profit (after Minority Interest) was Rs 2,936 million, YoY growth of 313.6%.
  • PAT for Q4FY23 was impacted on account of derecognition of deferred tax of Rs 1,197 million.
  • Adjusted for the above item, PAT growth for Q4FY24 would have been 54%.
  • As per IQVIA data, for Q4FY24, the company registered a growth of 1.4% YoY vs. the Indian Pharmaceutical Market (IPM) which grew by 5.7%

FY24 Financial Highlights:

  • Total Revenue from Operations was Rs 1,26,676 million, YoY growth of 9.2%.
  • India sales were Rs 84,337 million, YoY growth of 5.4%.
  • International sales were Rs 40,024 million, YoY growth of 16.4%.
  • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 22,455 million, resulting in EBITDA margin of 17.7% vs. 13.9% in FY23. EBITDA increased by 39.5% YoY.
  • R&D expenses for FY24 was Rs 5,229 million, or 4.1% of total revenue from operations compared to Rs 5,394 million in FY23 at 4.7% of total revenue from operations
  • Profit before tax (PBT) before exceptional item was Rs 21,446 million, a growth of 52.3% compared to Rs 14,078 million in FY23.
  • Net Profit (after Minority Interest) was Rs 17,958 million, YoY growth of 82.5%.
  • PAT for FY23 was impacted on account of derecognition of deferred tax of Rs 1,197 million. Adjusted for the above item, PAT growth for FY24 would have been 62.7%.
  • As per IQVIA data, for FY24, the company registered a growth of 6.2% YoY, vs. the Indian Pharmaceutical Market (IPM) which grew by 7.6%
  • We are pleased to share that the international business has crossed revenue of Rs 40 billion in FY24.

Commenting on the FY24 results, Vikas Gupta, CEO, Alkem said "Our focus has been to improve EBIDTA margin during the year, on the back of benefits through various cost -control initiatives being implemented along with favourable API prices. Continuing our trend of improved performance, Q4FY24 builds on the momentum gained from previous quarters with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in US. Lower Opex across our manufacturing facilities and R&D also aided EBDITA margin. Our Biosimilars and international business has delivered strong growth across geographies. Our anti-diabetic portfolio continues to outperform the market. We are committed to carrying forward the momentum of better operational performance, building on our recent success."

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q3FY24 & 9MFY24 results:

Q3FY24 Financial Performance:

  • Total Revenue from Operations: Rs 33,239 million, a YoY growth of 9.3%.
    • India sales: Rs 22,328 million, a YoY growth of 12.1%.
    • International sales: Rs 10,240 million, a YoY growth of 3.1%.
  • EBITDA: Rs 7,076 million, resulting in an EBITDA margin of 21.3% compared to 19.7% in Q3FY23, indicating an 18.1% YoY increase.
  • R&D expenses: Rs 1,111 million, representing 3.3% of total revenue from operations, compared to Rs 1,297 million in Q3FY23 at 4.3% of total revenue from operations.
  • Profit before tax (PBT) before exceptional item: Rs 7,062 million, a growth of 31.0% compared to Q3FY23.
  • Net Profit (after Minority Interest): Rs 5,950 million, a YoY growth of 30.8%.

9MFY24 Financial Performance:

  • Total Revenue from Operations: Rs 97,318 million, a YoY growth of 11.9%.
    • India sales: Rs 64,613 million, a YoY growth of 7.9%.
    • International sales: Rs 30,928 million, a YoY growth of 19.8%.
  • EBITDA: Rs 18,435 million, resulting in an EBITDA margin of 18.9% compared to 14.4% in 9MFY23, indicating a 46.8% YoY increase.
  • R&D expenses: Rs 3,472 million, representing 3.6% of total revenue from operations, compared to Rs 3,922 million in 9MFY23 at 4.5% of total revenue from operations.
  • Profit before tax (PBT) before exceptional item: Rs 17,648 million, a growth of 61.4% compared to 9MFY23.
  • Net Profit (after Minority Interest): Rs 15,022 million, a YoY growth of 64.5%.

Commenting on the results, Dr Vikas Gupta, CEO, Alkem said, "Continuing our trend of improved performance, Q3 builds on the momentum gained in H1 with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in US market resulting in improved EBITDA margins. Our domestic business has outperformed IPM growth by 20bps. Our international business has delivered steady growth, although US business de-grew on the back of the high base of last year led by flu season. In non-US business across geographies, we achieved very healthy growth. Our biosimilars business is performing impressively and witnessing significant traction in the domestic biosimilars market with Enzene’s portfolio of 7 products. We are committed to carrying forward the momentum of better operational performance, building on our recent successes."

 

 

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Total Revenue from Operations was Rs 34,402 million, YoY growth of 11.7%
      • India sales were Rs 23,278 million, YoY growth of 5%
      • International sales were Rs 10,542 million, YoY growth of 27.1%
    • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) was Rs 7,467 million, resulting in an EBITDA margin of 21.7% vs. 14.7% in Q2FY23. EBITDA increased by 64.5% YoY.
    • R&D expenses for the quarter were Rs 1,158 million, or 3.4% of total revenue from operations compared to Rs 1,305 million in Q2FY23 at 4.2% of total revenue from operations
    • Profit before tax (PBT) after the exceptional item was Rs 6,480 million, a growth of 61.1% compared to Q2FY23
      • Exceptional item of Rs 577 million debit was on account of impairment of fixed assets
    • Net Profit (after Minority Interest) was Rs 6,205 million, with YoY growth of 87.6%
  • H1FY24:
    • Total Revenue from Operations was Rs 64,079 million, YoY growth of 13.3%
      • India sales were Rs 42,285 million, YoY growth of 5.8%
      • International sales were Rs 20,688 million, YoY growth of 30.2%
    • Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) was Rs 11,359 million, resulting in an EBITDA margin of 17.7% vs. 11.6% in H1FY23. EBITDA increased by 72.9% YoY
    • R&D expenses for H1FY24 was Rs 2,360 million, or 3.7% of total revenue from operations compared to Rs 2,625 million in H1FY23 at 4.6% of total revenue from operations
    • Profit before tax (PBT) after the exceptional item was Rs 10,009 million, a growth of 80.6% compared to H1FY23
      • Exceptional item of Rs 577 million debit was on account of impairment of fixed assets
    • Net Profit (after Minority Interest) was Rs 9,073 million, YoY growth of 97.9%

Commenting on the results, Sandeep Singh, Managing Director, Alkem said, " Continuing our trend of improved performance, Q2 builds on the momentum gained in Q1 with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in US market and increased operating leverage, resulting in improved EBITDA margins. Domestic growth for the quarter remained subdued due to sporadic monsoon. However, we observed significant traction in the domestic market during the month of September and anticipate continued momentum in the coming quarter. Our international business, both US and Non-US market maintains its robust performance, which was evident in Q1 and continues to flourish. Our biosimilars portfolio is performing impressively, with Enzene’s latest product addition (Ranibizumab), taking the product suite to 7, and witnessing significant traction in the domestic biosimilars market. We are committed to carrying forward the momentum of better operational performance, building on our recent successes."

Result PDF

Pharmaceuticals company Alkem Laboratories announced Q1FY24 results:

  • Total revenue from operations was Rs 29,677 million, YoY growth of 15.2%
    • India sales were Rs 19,007 million, YoY growth of 6.7%
    • International sales were Rs 10,146 million, YoY growth of 33.4%
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) was Rs 3,892 million, resulting in an EBITDA margin of 13.1% vs. 7.9% in Q1FY23. EBITDA increased by 91.5% YoY.
  • R&D expenses for Q1FY24 were Rs 1,202 million, or 4.1% of total revenue from operations compared to Rs 1,320 million in Q1FY23 at 5.1% of total revenue from operations.
  • Profit before tax (PBT) was Rs 3,529 million, a growth of 132.3% compared to Q1FY23.
  • Net profit (after Minority Interest) was Rs 2,867 million, YoY growth of 124.6%.

Commenting on the results, Sandeep Singh, Managing Director, Alkem said, "We are starting the year on a healthy note, showcasing better operational performance driven by improved margins resulting from softening of select raw material prices, favourable currency impact, easing of freight cost and implementation of some of our cost optimization efforts. Our acute business growth was impacted by the delayed onset of monsoon in certain parts of the country, yet we maintain an optimistic outlook for improved growth in Q2. International business achieved robust sales during the quarter, driven by substantial growth in our US operations and complemented by strong performance in non-US markets. Our biosimilar franchise, Enzene is steadily expanding its product portfolio in India, with two successful launches this quarter, bringing the total count of products to six—an impressive achievement for the company. Our cost optimization initiatives have started yielding tangible results and we remain committed to further unlocking operational efficiencies going forward.”

 

 

Result PDF

Trending News

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Published on 17-Dec-2025 09:01

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL).

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL)

Published on 17-Dec-2025 09:00

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Published on 16-Dec-2025 09:05

KIMS has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Krishna Institute of Medical Sciences (KIMS) has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Published on 16-Dec-2025 09:03

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding 

Published on 16-Dec-2025 09:01

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Published on 16-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status